> Have you not noticed how most of the data is not even reported on now and near all previous studies stopped at three months?
No, I haven’t noticed this. Do you mean reported in the media? I was never looking there for safety trial results. Do you mean in journals? Then that’s the just wrong—as is the claim that they stop at 3 months. You can look up phase 4 trials, for instance [0]:
> In addition to the standard ongoing (phase 4) trials, people who took part in the phase 3 trials of approved vaccines are continuing to be followed up (up to 2 years after their second dose) to collect more data – for example on safety, asymptomatic infection, and how long protection from the vaccines lasts.
Even the original BioNTech(Pfizer) clinical trial reports it’s methodology of surveying serious side effects for up to 6 months after second dose, which makes it a 7+ month study overall [1]
I mean the UK stopped reporting vaxxed vs unvaxxed back in May and I believe they've also stopped or reduced reporting on birth rates. There are other reports that have stopped but I'd have to go digging to grab them again.
That Pfizer trial ended at 3.5 months because 97% of the control group got vaccinated.
No, I haven’t noticed this. Do you mean reported in the media? I was never looking there for safety trial results. Do you mean in journals? Then that’s the just wrong—as is the claim that they stop at 3 months. You can look up phase 4 trials, for instance [0]:
> In addition to the standard ongoing (phase 4) trials, people who took part in the phase 3 trials of approved vaccines are continuing to be followed up (up to 2 years after their second dose) to collect more data – for example on safety, asymptomatic infection, and how long protection from the vaccines lasts.
Even the original BioNTech(Pfizer) clinical trial reports it’s methodology of surveying serious side effects for up to 6 months after second dose, which makes it a 7+ month study overall [1]
[0] https://www.bhf.org.uk/informationsupport/heart-matters-maga...
[1] https://www.nejm.org/doi/10.1056/NEJMoa2034577